Genital Herpes Vaccine
"Findings Recommend Herpes Vaccine for Human Trials," Focus, January 14, 2005.
"Herpes Vaccine Developed at HMS Licensed for Preclinical Trials", Focus, March 7, 2008.
"Acambis initiates pre-clinical testing with herpes vaccine from Harvard Medical School", Press Release, February 25, 2008
“Sanofi Pasteur Completes the Acquisition of Acambis”, Press Release, September 25, 2008
How can you help our genital herpes vaccine research?
Thank you for your interest in making a gift to the Knipe Lab Research Fund.
Your gift can be made using the secure online gift form available at:
https://post.harvard.edu/olc/pub/HAA/onlinegiving/showGivingForm.jsp?form_id=103
This form is also available at “Giving to HMS” in the Resources section on the HMS homepage.
Once in the gift form, please select “Harvard Medical School” from the drop-down list of schools and then from the drop-down list of Funds, please select “Friends of Harvard Medicine”. To ensure that your gift is directed to the Knipe Lab, please type “Knipe Lab Research Fund (520-362612)” in the “Additional Information” section of the form. Your gift will then be directed to the Knipe Lab Research Fund.
I would like to take this opportunity to thank you for your generous support of our research.
Many have written to ask how they can help support our research. A couple of possibilities are:
1. You can support our research directly by contacting the Harvard Medical School Office of Resource Development, where you can receive further information on how to make a gift. Contact Linda Jones at Linda_Jones@hms.harvard.edu, and she can confer with you about making a contribution to this research and answer any questions you may have. You can also send a contribution, along with a brief note indicating that your gift supports my work on the genital herpes vaccine, directly to:
Office of Resource Development
Harvard Medical School
401 Park Drive, Suite 22W
Boston, MA 02215
2. Contact your US Congressional representatives and senators and ask them to support NIH research in general and genital herpes research in particular. NIH funding has been flat for several years, and research funding for herpes has been decreasing over the past few years
Publications on the Vaccine
Da Costa, X.J., C.A. Jones and D.M. Knipe. 1999. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proceedings of the National Academy of Sciences, USA 96:6994-6998. (pdf)
Da Costa, X.J., M.F. Kramer, J. Zhu, M.A. Brockman and D.M. Knipe. 2000. Construction, phenotypic analysis and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. Journal of Virology 74:7963-7971. (pdf)
Hoshino, Y., S.K. Dalai, K. Wang, L. Pesnicak, T.Y. Lau, D.M. Knipe, J.I. Cohen, and S.E. Straus. 2005. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Journal of Virology 79:410-418. (pdf)
Dudek, T. and D. M. Knipe. 2006. Replication-defective viruses as vaccines and vaccine vectors. Virology. 344: 230-239. This paper reviews the use of replication-defective viruses as vaccines. (pdf)
van Lint, A.L., E. Torres-Lopez, D.M. Knipe. 2007. Immunization with a replication-defective herpes simplex virus-2 mutant reduces herpes simplex virus-1 infection and prevents ocular disease. Virology. 368: 227-31. This paper shows that dl5-29 can protect mice against HSV-1 infection also. (pdf)
Dudek, T., L. Mathews, D.M. Knipe. 2007. Disruption of the UL41 Gene in the Herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology. 372:165-75. (pdf)
Hoshino, Y., L. Pesnicak, K.C. Dowdell, J. Lacayo, T. Dudek, D.M. Knipe, S.E. Straus, J.I. Cohen. 2008. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine. 26: 4034-40. (pdf)
|
